{"id":68994,"date":"2026-03-12T15:22:39","date_gmt":"2026-03-12T15:22:39","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=68994"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"cjc-1295-with-dac","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/cjc-1295-with-dac\/","title":{"rendered":"CJC-1295 cu DAC"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is CJC-1295 with DAC?<\/h3>\n

CJC-1295 cu DAC<\/strong> is a synthetic analog of growth-hormone-releasing hormone (GHRH 1-29) modified with a Drug Affinity Complex (DAC)<\/strong> that binds plasma albumin covalently. The albumin binding extends plasma half-life from ~30 minutes to approximately 7\u00a0days, enabling weekly or twice-weekly research dosing. It is supplied in 2\u00a0mg and 5\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Ce beneficii ofer\u0103 MedsBase:<\/strong> Peptide liofilizate pentru cercetare \u00b7 puritate HPLC \u226599% (certificat de analiz\u0103 la cerere) \u00b7 Ambalaj discret stabil la temperatur\u0103 \u00b7 Curierat worldwide de peptide \u00b7 Peste 1.400 de recenzii verificate ale clien\u021bilor<\/a><\/div>\n

\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifica\u021bii<\/th>\nDetaliu<\/th>\n<\/tr>\n<\/thead>\n
Num\u0103r CAS<\/strong><\/td>\n863288-34-0<\/td>\n<\/tr>\n
Formula molecular\u0103<\/strong><\/td>\nC165<\/sub>H269<\/sub>N47<\/sub>O46<\/sub><\/td>\n<\/tr>\n
Greutate molecular\u0103<\/strong><\/td>\n3647.25 Da<\/td>\n<\/tr>\n
Secven\u021b\u0103<\/strong><\/td>\nD-Ala-Tyr-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-NH2<\/sub> conjugated to maleimidopropionyl-Lys (DAC linker for albumin binding)<\/td>\n<\/tr>\n
Form\u0103<\/strong><\/td>\nPulbere liofilizat\u0103 (sau a\u0219a cum este furnizat)<\/td>\n<\/tr>\n
Puritate<\/strong><\/td>\n\u226599% (verificat prin HPLC, COA la cerere)<\/td>\n<\/tr>\n
Depozitare<\/strong><\/td>\nLiofilizat: 2\u20138\u00b0C (frigider) pentru stocul de lucru; \u221220\u00b0C pentru depozitarea pe termen lung a vialelor nefolosite. Reconstituit: 2\u20138\u00b0C, utilizat \u00een ~30 de zile. Proteja\u021bi de lumin\u0103. Nu \u00eenghe\u021ba\u021bi-decongela\u021bi solu\u021bia reconstituit\u0103.<\/td>\n<\/tr>\n
Solubilitate<\/strong><\/td>\nAp\u0103 bacteriostatic\u0103 (recomandat\u0103) sau ap\u0103 steril\u0103 pentru perioade mai scurte de utilizare<\/td>\n<\/tr>\n
Utilizare \u00een cercetare<\/strong><\/td>\nDoar pentru utilizare \u00een cercetare de laborator. Nu este destinat pentru uz diagnostic sau terapeutic uman sau veterinar.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is CJC-1295 with DAC?<\/h2>\n

CJC-1295<\/strong> is a synthetic 30-amino-acid analog of growth-hormone-releasing hormone (GHRH), specifically a modified form of the biologically-active GHRH (1-29) fragment. The “with DAC<\/strong>” suffix refers to a proprietary Drug Affinity Complex (DAC)<\/strong> \u2014 a maleimidopropionic acid residue attached to lysine-30 \u2014 which forms a covalent bond with serum albumin cysteine-34 in vivo<\/em>.<\/p>\n

That albumin tether is the key innovation. Native GHRH has a plasma half-life measured in minutes (rapid DPP-IV degradation); CJC-1295 with DAC circulates bound to albumin for approximately 7 zile<\/strong>, enabling weekly or twice-weekly research dosing while sustaining GH\/IGF-1 elevation between injections. This is a fundamentally different pharmacokinetic profile from the “without DAC” version (sometimes called Mod GRF 1-29) which retains native GHRH’s short half-life. Developed by ConjuChem, CJC-1295 is destinat doar pentru cercetare de laborator<\/strong> and is not intended for human or veterinary diagnosis or therapy. For mechanism, research context, and stacking protocols, see our Ipamorelin & CJC-1295 research guide<\/a>.<\/p>\n

Mechanism of Action \u2014 Extended-Release GHRH Agonism<\/h2>\n

CJC-1295 with DAC acts through two sequential mechanisms:<\/p>\n